product summary
Loading...
company name :
R&D Systems
product type :
other
product name :
Simple Plex Control for Human CD40 Ligand/TNFSF5
catalog :
897160
quantity :
1 Each
price :
145 USD
more info or order :
product information
master code :
897160
SKU :
897160
product name :
Simple Plex Control for Human CD40 Ligand/TNFSF5
unit size :
1 Each
target :
CD40 Ligand/TNFSF5
category :
Simple Plex Assays
species :
Human
applications :
Simple Plex Automated Immunoassay
extended description :
Control for use with Human CD40 Ligand/TNFSF5 Simple Plex Assay Cartridge Kit
USD :
145 USD
product details :
Control for use with Human CD40 Ligand/TNFSF5 Simple Plex Assay Cartridge Kit
alt names :
CD154, CD154 antigen, CD40 antigen ligand, CD40 ligand, CD40L, CD40-L, CD40LG, CD40LIGM, gp39, hCD40L, HIGM1, T-B cell-activating molecule, T-BAM, T-cell antigen Gp39, TNF-related activation protein, TNFSF5, TNFSF5IMD3, TRAP, TRAPtumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome), tumor necrosis factor (ligand) superfamily member 5, Tumor necrosis factor ligand superfamily member 5
storage :
Store lyophilized controls at 2-8 ░C. Lyophilized controls are stable for up to 12 months from date of receipt. Reconstituted controls are stable for up to 6 months from date of preparation when stored at <= -70 ░C. Storage at -20░ C is not recommended. Individual frozen aliquots of low and high controls are designed as single-use entities. Thaw directly before use and discard any remaining volume.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
browse more products
questions and comments